Updated:
SM-Sino Technology Investment
SM-Sino Technology Investment is a venture capital firm focused on the healthcare sector. It invests in biotech companies from seed rounds to pre-IPO stages.
Overview
SM-Sino Technology Investment is a venture capital firm focused on the healthcare sector. It invests in biotech companies from seed rounds to pre-IPO stages. The firm has made 2 investments, including a Series B investment in Oncocross on September 04, 2020.
General information
Firm type
Private Equity
Year founded
2015
Location
Region
Asia
Country
South Korea
City
Seoul
Corporate office
11, Saechang-ro, Mapo-gu, Seoul, Republic of Korea
Sector focus
Frequently asked questions
Who founded SM-Sino Technology Investment?
The firm was founded by a group of doctors, entrepreneurs, and venture capitalists. It does not publicly name individual founders on its website or through other primary sources.
What is SM-Sino Technology Investment's investment focus?
The firm invests exclusively in the pharmaceuticals and healthcare sectors. Its stated expertise ranges from early-stage technologies and incubation through to pre-IPO rounds.
How does SM-Sino source its deals?
SM-Sino's website emphasizes a hands-on approach that identifies early-stage technologies and supports startups through incubation and acceleration. The founders' combined medical and entrepreneurial backgrounds imply a network-driven sourcing model within the South Korean healthcare ecosystem.
Which sectors does SM-Sino explicitly avoid?
SM-Sino states a specific focus on pharmaceuticals and healthcare. There is no indication that it invests in sectors such as consumer technology, enterprise software, or industrial tech.
Profile maintained by Altss. Updated: . To correct this record or make a privacy request, send the page URL and your evidence to privacy@altss.com; corrections are free.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: